See more : Brookfield Infrastructure Corpo (BIPH) Income Statement Analysis – Financial Results
Complete financial analysis of GRI Bio, Inc. (GRI) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of GRI Bio, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Chemtech Industrial Valves Limited (CHEMTECH.BO) Income Statement Analysis – Financial Results
- Sekisui House, Ltd. (SKHSY) Income Statement Analysis – Financial Results
- Identiv, Inc. (INVE) Income Statement Analysis – Financial Results
- Corner Growth Acquisition Corp. 2 (TRONW) Income Statement Analysis – Financial Results
- PETRONAS Chemicals Group Berhad (5183.KL) Income Statement Analysis – Financial Results
GRI Bio, Inc. (GRI)
About GRI Bio, Inc.
GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on treating inflammatory, fibrotic, and autoimmune diseases in the United States. Its product pipeline comprises GRI-0621, which is in phase II clinical development for the treatment of idiopathic pulmonary fibrosis; GRI-0803 which is in phase I trial for the treatment of systematic lupus erythematosus; GRI-0124, which is in pre-clinical development for the treatment of primary sclerosing cholangitis; and GRI-0729 in pre-clinical development. The company also develops ADAIR and ADMIR for treatment of attention -deficit/hyperactivity disorder. GRI Bio, Inc. was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 21.77M | 0.00 | 0.00 | 100.00K | 0.00 | 0.00 |
| Cost of Revenue | 57.00K | 206.00K | 73.00K | 0.00 | 735.00 | 612.00 |
| Gross Profit | 21.71M | -206.00K | -73.00K | 100.00K | -735.00 | -612.00 |
| Gross Profit Ratio | 99.74% | 0.00% | 0.00% | 100.00% | 0.00% | 0.00% |
| Research & Development | 3.23M | 242.00K | 249.00K | 3.71M | 1.88M | 3.51M |
| General & Administrative | 1.49M | 2.00M | 813.00K | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 2.96M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 8.10M | 2.00M | 813.00K | 1.11M | 1.27M | 800.08K |
| Other Expenses | 102.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 11.33M | 2.24M | 1.06M | 4.81M | 3.15M | 4.31M |
| Cost & Expenses | 11.39M | 2.24M | 1.06M | 4.89M | 3.15M | 4.31M |
| Interest Income | 0.00 | 26.00K | 0.00 | 0.00 | 0.00 | 1.06K |
| Interest Expense | 2.08M | 653.00K | 547.00K | 34.00K | 197.03K | 0.00 |
| Depreciation & Amortization | 57.00K | 50.00K | 73.00K | 75.00K | 735.00 | 612.00 |
| EBITDA | -10.90M | -2.51M | -9.21M | -4.71M | -3.27M | -4.31M |
| EBITDA Ratio | -50.07% | 0.00% | 0.00% | -4,713.00% | 0.00% | 0.00% |
| Operating Income | -11.39M | -2.24M | -1.06M | -4.79M | -3.15M | -4.31M |
| Operating Income Ratio | -52.31% | 0.00% | 0.00% | -4,788.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -1.65M | -978.00K | -8.24M | -34.00K | -310.07K | 1.06K |
| Income Before Tax | -13.04M | -3.22M | -1.56M | -4.82M | -3.46M | -4.31M |
| Income Before Tax Ratio | -59.89% | 0.00% | 0.00% | -4,822.00% | 0.00% | 0.00% |
| Income Tax Expense | 2.77M | 325.00K | -50.00K | -131.30K | 5.00 | -2.00 |
| Net Income | -13.04M | -3.54M | -1.51M | -4.82M | -3.46M | -4.31M |
| Net Income Ratio | -59.89% | 0.00% | 0.00% | -4,822.00% | 0.00% | 0.00% |
| EPS | -28.25 | -8.43 | -4.65 | -14.87 | -10.68 | -1.73K |
| EPS Diluted | -28.25 | -8.43 | -4.65 | -14.87 | -10.68 | -1.73K |
| Weighted Avg Shares Out | 461.57K | 420.00K | 324.42K | 324.33K | 324.33K | 2.49K |
| Weighted Avg Shares Out (Dil) | 461.57K | 420.00K | 324.42K | 324.33K | 324.33K | 2.49K |
GRI Bio to Present at LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar
Live webcast on Wednesday, May 1 st at 3:00 PM ET LA JOLLA, CA, April 25, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer...
GRI Bio Expands Intellectual Property Protection for Proprietary Natural Killer T (NKT) Cell Modulators with Issuance of Korea Patent
Ongoing efforts to build a robust global patent estate for a growing pipeline targeting high-value indications in need of innovation
GRI Bio Announces Abstract Accepted for Poster Presentation at the 2024 American Thoracic Society International Conference
LA JOLLA, CA, April 08, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (NKT) cell modulators for the treatment of inflammatory, fibrotic and...
GRI Bio Reports Full Year 2023 Financial Results and Provides Corporate Update
Ongoing Phase 2a biomarker study evaluating lead program GRI-0621 for the treatment of Idiopathic Pulmonary Fibrosis (IPF) with interim data expected H1 2024 and topline data expected H2 2024
GRI Bio to Present at the MedInvest Biotech & Pharma Investor Conference
Live webcast on Wednesday, April 3 rd at 10:10 AM ET LA JOLLA, CA, March 28, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer...
GRI Bio Announces Notice of Allowance for Canadian Patent Covering Proprietary Natural Killer T (NKT) Cell Modulators
Company advancing an innovative pipeline of NKT cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases
GRI Bio Receives MHRA Authorization to Conduct Phase 2a Biomarker Study Evaluating GRI-0621 in the United Kingdom
MHRA authorization expands ongoing U.S. Phase 2a biomarker study evaluating lead program GRI-0621 for the treatment of Idiopathic Pulmonary Fibrosis (“IPF”) with interim data expected H1 2024 and topline data H2 2024
Top 4 Health Care Stocks That Are Preparing To Pump This Month - ProSomnus (NASDAQ:OSA), GRI Bio (NASDAQ:GRI)
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
Why Is GRI Bio (GRI) Stock Down 21% Today?
GRI Bio (NASDAQ: GRI ) stock is taking a beating on Friday as investors in GRI react to the pricing of a public offering for the biotechnology company's shares. According to a press release from GRI Bio, this public offering includes 5...
GRI Bio Announces Pricing of $5.5 Million Public Offering
LA JOLLA, CA, Feb. 02, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell modulators for the treatment of inflammatory, fibrotic and...
Source: https://incomestatements.info
Category: Stock Reports